Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcgRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1

被引：0
|
作者：
Carneiro, Ana
Yachnin, Jeffrey
Aljumaily, Raid
Abel, Edvard
Falchook, Gerald Steven
Ji, Yan
Borggren, Marie
Martensson, Linda
Gertsson, Susanne
Karlsson, Ingrid
Teige, Ingrid
Tehranchi, Ramin
Wallin, Johan Erik
Chisamore, Michael Jon
Frendeus, Bjorn
McAllister, Andres
机构：
[1] Skane Univ Hosp, Dept Hematol Oncol & Radiat Phys, Comprehens Canc Ctr, Lund, Sweden
[2] Karolinska Comprehens Canc Ctr, Stockholm, Sweden
[3] OU Hlth Stephenson Canc Ctr, Oklahoma City, OK USA
[4] Sahlgrens Univ Hosp, Gothenburg, Sweden
[5] HealthONE, Sarah Cannon Res Inst, Denver, CO USA
[6] Hlth Partners, St Paul, MN USA
[7] BioInvent, Lund, Sweden
[8] Merck & Co Inc, Rahway, NJ USA
[9] BioInvent Int, Lund, Sweden
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2593
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Platform trial of BI 754091, an anti-PD-1 antibody, in patients with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.
    Hussein, Maen A.
    Bendell, Johanna C.
    Arkenau, Hendrik-Tobias
    Chu, Quincy S.
    Hansen, Aaron Richard
    Erzen, Damijan
    Sun Zhichao
    Lucarelli, Anthony
    Percent, Ivor John
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [2] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Hiro Sato
    Noriyuki Okonogi
    Takashi Nakano
    International Journal of Clinical Oncology, 2020, 25 : 801 - 809
  • [3] Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment
    Sato, Hiro
    Okonogi, Noriyuki
    Nakano, Takashi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (05) : 801 - 809
  • [4] Phase I/Ib Clinical Trial of Sabatolimab, an Anti-TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti-PD-1 Antibody, in Advanced Solid Tumors
    Curigliano, Giuseppe
    Gelderblom, Hans
    Mach, Nicolas
    Doi, Toshihiko
    Tai, David
    Forde, Patrick M.
    Sarantopoulos, John
    Bedard, Philippe L.
    Lin, Chia-Chi
    Hodi, F. Stephen
    Wilgenhof, Sofie
    Santoro, Armando
    Sabatos-Peyton, Catherine A.
    Longmire, Tyler A.
    Xyrafas, Alexandros
    Sun, Haiying
    Gutzwiller, Sabine
    Manenti, Luigi
    Naing, Aung
    CLINICAL CANCER RESEARCH, 2021, 27 (13) : 3620 - 3629
  • [5] Vibostolimab, an anti-TIGIT antibody, as monotherapy and in combination with pembrolizumab in anti-PD-1/PD-L1-refractory NSCLC
    Ahn, M-J.
    Niu, J.
    Kim, D-W.
    Rasco, D.
    Mileham, K. F.
    Chung, H. C.
    Vaishampayan, U. N.
    Maurice-Dror, C.
    Lo Russo, P.
    Golan, T.
    Chartash, E.
    Chen, D.
    Healy, J.
    Rajasagi, M.
    Lee, D. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S887 - S887
  • [6] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Seto, Takashi
    Hirai, Fumihiko
    Takenoyama, Mitsuhiro
    Nosaki, Kaname
    Tsurutani, Junji
    Kaneda, Hiroyasu
    Iwasa, Tsutomu
    Kawakami, Hisato
    Noguchi, Kazuo
    Shimamoto, Takashi
    Nakagawa, Kazuhiko
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (03) : 347 - 354
  • [7] Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takashi Seto
    Fumihiko Hirai
    Mitsuhiro Takenoyama
    Kaname Nosaki
    Junji Tsurutani
    Hiroyasu Kaneda
    Tsutomu Iwasa
    Hisato Kawakami
    Kazuo Noguchi
    Takashi Shimamoto
    Kazuhiko Nakagawa
    Investigational New Drugs, 2016, 34 : 347 - 354
  • [8] Clinical benefit of neoadjuvant anti-PD-1/PD-L1 utilization among different tumors
    Li, Zhiyang
    Wu, Xin
    Zhao, Yanjie
    Xiao, Yinan
    Zhao, Yunuo
    Zhang, Ting
    Li, Hui
    Sha, Fushen
    Wang, Yating
    Deng, Lei
    Ma, Xuelei
    MEDCOMM, 2021, 2 (01): : 60 - 68
  • [9] Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
    Francesco Spagnolo
    Andrea Boutros
    Federica Cecchi
    Elena Croce
    Enrica Teresa Tanda
    Paola Queirolo
    BMC Cancer, 21
  • [10] Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
    Spagnolo, Francesco
    Boutros, Andrea
    Cecchi, Federica
    Croce, Elena
    Tanda, Enrica Teresa
    Queirolo, Paola
    BMC CANCER, 2021, 21 (01)
12345